Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Mini-Primaquine Does Help Stop People Infecting Mosquitos with Malaria

By Liverpool School of Tropical Medicine | February 5, 2018

A single dose of primaquine is thought to stop people with P. falciparum malaria infecting mosquitoes, which could help bring down malaria transmission. In this Cochrane Review update, prepared by an international team of researchers and co-ordinated through the Cochrane infectious Diseases Group (CIDG) based at LSTM, the researchers added recent data to examine this question. Their findings are relevant to the global recommendation by the World Health Organization that mini-primaquine be given to all people unwell with malaria in areas where transmission is low to reduce transmission further.

In these new trials, researchers test infectivity of people by getting mosquitoes to feed on people or their blood and then measuring whether the mosquitoes become infected with malaria.  For the currently recommended dose of 0.25 mg/kg, the calculations across 3 trials with 105 participants show the percentage of people infectious 2 to 3 days after treatment is reduced from 14% of people in the control group to 2% in the primaquine group. A little later, a week after the treatment had been started, the absolute effect was smaller- with 4% infectious in the control group and 1% in the primaquine group. This shows that primaquine does reduce transmission-but it may not be to the extent that people had hoped for.

Many potentially infectious people with malaria are asymptomatic, so few would seek treatment. The question of whether a partial reduction in infectiousness for a few days would materially affect the community malaria burden is still unanswered, although malaria modelers have generally concluded that the increased impact would be marginal.

Dr. Patricia Graves from James Cook University in Cairns, Australia is first author on the review. She said: “The trials show infectiousness is reduced with low dose primaquine, but the effects were relatively modest and short lived. We also do not know if this then would have any effect on malaria transmission at community level. Given the current evidence, it might be better for policy makers to concentrate on other approaches to help reduce transmission.”

SOURCE: Liverpool School of Tropical Medicine


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE